A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Lasmiditan
Drug: Placebo

Registration Number: NCT03670810

Lead Sponsor: Eli Lilly and Company

Brief Summary: The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 1633

Inclusion Criteria

Migraine with or without aura fulfilling the International Headache Society (IHS) diagnostic criteria 1.1 and 1.2.1
History of disabling migraine for at least 1 year
Migraine onset before the age of 50 years
History of 3 to 8 migraine attacks per month (<15 headache days per month) during the past 3 months
MIDAS score ≥11
Able and willing to complete an eDiary to record the details of each migraine attack treated with study drug
Women of child-bearing potential must be using or willing to use a highly effective form of contraception
Agree not to post any personal medical data or information related to the study on any website or social media site until the entire trial has completed

Exclusion Criteria

Known hypersensitivity to lasmiditan, or to any excipient of lasmiditan oral tablets
History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing the participant at increased risk of seizures
History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders
History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or neuropathy)
History of orthostatic hypotension with syncope
Significant renal or hepatic impairment in the opinion of the investigator or if they meet hepatic monitoring criteria
Participants who, in the investigator's judgment, are actively suicidal and therefore deemed to be at significant risk for suicide
History, within past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (eg, hemicranias continua, medication overuse headache where headache frequency is ≥15 headache days per month)
Use of more than 3 doses per month of either opioids or barbiturates
Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within 3 months prior to screening
Pregnant or breast-feeding women
History of drug or alcohol abuse/dependence within 1 year prior to screening
Any medical condition or clinical laboratory test which in the judgment of the investigator makes the participant unsuitable for the study
Currently enrolled in any other clinical study involving an investigational product
Relatives of, or staff directly reporting to, the Investigator
Participants who are employees of the sponsor

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
100 milligram (mg) Lasmiditan	Placebo	Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
200 mg Lasmiditan	Placebo	Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Control 1 Sequence	Placebo	Control 1: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Control 2 Sequence	Placebo	Control 2: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
100 mg Lasmiditan Maximum Extended Enrollment (MEE)	Placebo	Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
200 mg Lasmiditan MEE	Placebo	Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Control 1 Sequence MEE	Placebo	Control 1: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Control 2 Sequence MEE	Placebo	Control 2: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
200 mg Lasmiditan	Lasmiditan	Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
200 mg Lasmiditan MEE	Lasmiditan	Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Open Label Extension	Lasmiditan	Participants initially received 100 mg Lasmiditan at the first OLE visit, with flexible dosing (50, 100, or 200 mg) thereafter to optimize efficacy and tolerability.
100 milligram (mg) Lasmiditan	Lasmiditan	Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Control 1 Sequence	Lasmiditan	Control 1: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Control 2 Sequence	Lasmiditan	Control 2: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
100 mg Lasmiditan Maximum Extended Enrollment (MEE)	Lasmiditan	Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Control 1 Sequence MEE	Lasmiditan	Control 1: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Control 2 Sequence MEE	Lasmiditan	Control 2: Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3. Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack	2 Hours Postdose	Pain-free is defined as mild, moderate, or severe headache pain becoming none at 2 hours postdose during the first attack.
Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 2 Out of 3 Attacks	2 Hours Postdose	To evaluate the 2 out of 3 primary consistency endpoint, the results of ITT evaluable attacks in the lasmiditan 100-mg and 200-mg groups will be assessed, and the ITT-evaluable attacks treated with placebo in the control group will be used for comparison. For participants with more than 3 ITT evaluable attacks, only the first 3 will be considered. Pain-free was defined as mild, moderate, or severe headache pain becoming none at the indicated assessment time.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With 24-Hour Sustained Pain Freedom During the First Attack	24 Hours	Sustained pain freedom defined as pain free at 2 and 24 hours with no rescue medication.
Percentage of Participants With 48-Hour Sustained Pain Freedom During First Attack	48 Hours Postdose	Sustained pain freedom defined as pain free at 2 and 48 hours with no rescue medication.
Percentage of Participants With Pain Relief at 2 Hours Post Dose During the First Attack	2 Hours Postdose	Headache pain-relief is defined as a reduction in pain severity from moderate or severe at baseline to mild or none, or a reduction in pain severity from mild at baseline to none, at the indicated assessment time.
Percentage of Participants With Pain Relief at 2 Hours Postdose in at Least 2 Out of 3 Attacks	2 Hours Postdose	Headache pain relief is defined as a reduction in pain severity from moderate to severe at baseline to mild or none at 2 hours postdose in at least 2 out of 3 attacks. To evaluate at least 2 out of 3 consistency endpoints, the results of ITT-evaluable attacks in the lasmiditan 100-mg and 200-mg groups will be assessed, and the ITT-evaluable attacks treated with placebo in the control group will be used for comparison. For participants with more than 3 ITT-evaluable attacks, only the first 3 with the same treatment will be considered.
Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack in Triptan Insufficient Responders.	2 Hours Postdose	Pain-free is defined as mild, moderate, or severe headache pain becoming none at 2 hours postdose during the first attack. A triptan insufficient responder is defined as having one of the following: 1) Scoring ≤5 on 4 questions from the Migraine Treatment Optimization Questionnaire (mTOQ-6) that defines participants with poor or very poor response to their current regimen; 2) Indicated they obtained pain freedom at 2 hours in 0 out of 3, or 1 out of 3 attacks when treated with the most recent triptan, or 3) are not currently taking triptan and discontinued their most recent triptan due to lack of efficacy, tolerability issue, or contradictions to a past triptan.
Percentage of Participants With no Disability as Measured by the Disability Item, at 2 Hours Postdose During the First Attack	2 Hours Postdose	Percentage of participants with no disability as measured by the disability item, at 2 hours postdose during the first attack. Disability was measured by determining the level of interference with normal activities with 4 response options including not at all; mild interference, marked interference; and need complete bed rest.
Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 2 Out of 3 Attacks in Triptan Insufficient Responders	2 Hours Postdose	Headache pain-free is defined as a reduction in pain severity from mild, moderate, or severe at baseline to none at the indicated assessment time. A subject is not counted as being pain-free at a specific time point if she or he used rescue or recurrence medication at or before the specific time point.
Percentage of Participants Free of Most Bothersome Symptom (MBS) Associated With Migraine at 2 Hours Postdose During the First Attack	2 Hours Postdose	MBS freedom is defined as the absence of the associated symptom of migraine (nausea, phonophobia, or photophobia) at the indicated assessment time that was identified at baseline as the most bothersome symptom.
Percentage of Participants Requiring Rescue Medication for Migraine Within 24 Hours of Treatment During the First Attack	24 Hours	Percentage of participants requiring rescue medication for migraine within 2 to 24 hours of treatment during the first attack
Percentage of Participants That Are Free of Symptoms Associated With Migraine at 2 Hours Postdose During the First Attack	2 Hours Postdose	Percentage of participants that are free of symptoms associated with migraine (photophobia, phonophobia, nausea, and vomiting) at 2 hours postdose during the first attack.
Percentage of Participants With Migraine Recurrence at 24 Hours During the First Attack	24 Hours	Percentage of participants with migraine recurrence at 24 hours during the first attack defined as return of any headache in participants who were pain free at 2 hours.
Percentage of Participants With Pain Freedom, Pain Relief, Freedom From MBS, and No Disability Postdose During First Attack	30 Minutes (Min) and 1 Hour (Hr) Postdose	Percentage of participants with pain freedom, pain relief, freedom from MBS, and no disability postdose during first attack.
Change From Baseline in Total Score as Measured by the Migraine Disability Assessment Test (MIDAS) Scale	Baseline, Week 16	The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of 5 items that reflect the number of days reported as missed, or with reduced productivity at work or home and social events. Each question is answered as the number of days during the past 3 months of assessment, ranging from 0 to 90, with the total score being the summation of the 5 numeric responses. A higher value is indicative of more disability.
Percentage of Participants Very Much or Much Better as Measured by Patient Global Impression of Change (PGI-C), at 2 Hours Postdose During the First Attack	2 Hours Postdose	The PGI-C is a one-item questionnaire that asks participants to provide their impression of change since taking the medicine. The PGI-C is measured using a 7-point Likert scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse. Reported are participants whose combined impression of change since taking the medicine was very much better and much better at 2 hours postdose.
Migraine Quality of Life Questionnaire (MQoLQ) Score at 24 Hours Post First Dose of Study During First Attack	24 Hours Post First Dose	The 24-hour Migraine Quality of Life Questionnaire (24-hr MQoLQ) has been specifically developed to measure the HRQoL of participants with migraine within a 24-hour period after having taken migraine medication A domain score is calculated by summing the responses to the 3 questions and the domain score ranges from 3 to 21, with lower scores indicating less impairment. The questionnaire will be administered 24 hours after dosing with study drug during each migraine. The analysis of variance (ANOVA) model was used with region and treatment adjusted for the overall treatment effect.
Percentage of Participants Satisfied With Their Treatment Measured by a 4-Item Questionnaire	Week 16	Treatment satisfaction was evaluated at the End of Study (EoS) visit by determining the participant's level of satisfaction (ranging from extremely dissatisfied to extremely satisfied); their willingness to take this treatment again (ranging from strongly disagree to strongly agree) and if they would they recommend this treatment to another participants (ranging from strongly disagree to strongly agree).
Change From Baseline in Utility at 24 Hours Postdose as Measured by the EuroQol 5-Dimension 5-Level Scale (EQ-5D-5L) at 24 Hours Postdose During First Attack	Baseline, 24 Hours Postdose	The EQ-5D-5L questionnaire is a participant-rated scale that assesses health status, it consists of 2 parts. The first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 5 possible levels of response (no problems, slight problems, moderate problems, severe problems, extreme problems).The EQ-5D can be used to generate a health state index score, which is used to compute quality-adjusted life years for utilization in health economic analyses. The health state index score is calculated based on the responses to the 5 dimensions, providing a single value on a scale from less than 0 (where 0 is a health state equivalent to death) to 1 (perfect health), with higher scores indicating better health utility. ANCOVA was used to assess the effect of Lasmiditan over placebo or control. The model includes fixed categorical effect of treatment and geographic region and baseline as covariate.
Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 3 Out of 4 Attacks	2 Hours Postdose	Headache pain-free is defined as a reduction in pain severity from mild, moderate, or severe to none at the indicated assessment time (2 hours postdose). To evaluate 3 out of 4 consistency endpoints; all ITT-evaluable attacks will be used. For the control group, the results of all ITT-evaluable attacks treated with lasmiditan 50 mg or placebo will be included. The control group is used for comparison. The population for 3 out of 4 consistency endpoints with sufficient number of successes or failures is defined as all participants who experienced at least 3 successes or 2 failures during ITT-evaluable attacks.
Percentage of Participants With Pain Relief at 2 Hours Postdose in at Least 3 Out of 4 Attacks	2 Hours Postdose	Headache pain-relief is defined as a reduction in pain severity from moderate or severe at baseline to mild or none, or a reduction in pain severity from mild at baseline to none, at the indicated assessment time (2 hours postdose). To evaluate 3 out of 4 consistency endpoints; all ITT-evaluable attacks will be used. For the control group, the results of all ITT-evaluable attacks treated with lasmiditan 50 mg or placebo will be included. The control group is used for comparison. The population for 3 out of 4 consistency endpoints with sufficient number of successes or failures is defined as all participants who experienced at least 3 successes or 2 failures during ITT-evaluable attacks.
Percentage of Participants With Associated Migraines Symptoms of Nausea, Vomiting, Photophobia, and Phonophobia Present at 2 Hours Postdose for First Attack	2 Hours Postdose	Presence of associated migraine symptoms at 2 hours postdose at first migraine attack, including each of the following: phonophobia, photophobia, nausea, and vomiting.

Trial Locations

Locations (136): KH der Barmherzigen Schwestern Linz BetriebsGesmbH
🇦🇹
Linz, Oberösterreich, Austria
Praxis für Neurologie und Psychiatrie
🇩🇪
Essen, North Rhine-Westphalia, Germany
Affiliated Hospital of Jiangsu University
🇨🇳
Zhenjiang, Jiangsu, China
First Affiliated Hospital of Gannan Medical University
🇨🇳
Ganzhou, Jiangxi, China
West China Hospital of Sichuan University
🇨🇳
Chengdu, Sichuan, China
Beijing Tiantan Hospital Affiliated to Capital Medical Univ
🇨🇳
Beijing, Beijing, China
Peking Union Medical College Hospital
🇨🇳
Beijing, China
The First Affiliated Hospital of Harbin Medical University
🇨🇳
Harbin, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
🇨🇳
Hangzhou, Zhejiang, China
Tianjin Medical University General Hospital
🇨🇳
Tianjin, China
Center for Clinical and Basic Research -CCBR
🇩🇰
Vejle, Denmark
Colorado Neurological Institute
🇺🇸
Englewood, Colorado, United States
Diamond Headache Clinic
🇺🇸
Chicago, Illinois, United States
Rehabilitation & Neurological Services LLC
🇺🇸
Huntsville, Alabama, United States
Island Neuro Associates,PC
🇺🇸
Plainview, New York, United States
Wuhan Union (Xiehe) Hospital
🇨🇳
Wuhan, Hubei, China
Xuanwu Hospital-Capital Medical University
🇨🇳
Beijing, Beijing, China
No.2 Hospital Affiliated to Jilin University
🇨🇳
Changchun City, Jilin, China
Guangzhou First People's Hospital
🇨🇳
Guangzhou, Guangdong, China
Barrow Neurological Institute
🇺🇸
Phoenix, Arizona, United States
Montefiore Headache Center
🇺🇸
Bronx, New York, United States
Georgetown University Hospital
🇺🇸
Washington, District of Columbia, United States
Universitätsklinik Innsbruck
🇦🇹
Innsbruck, Tirol, Austria
The First Affiliated Hospital Chongqing Medical University
🇨🇳
Chongqing, Chongqing, China
The First Affliated Hospital of Suzhou University
🇨🇳
Suzhou, Jiangsu, China
Dalian Municipal Central Hospital Affiliated of Dalian Medical University
🇨🇳
Dalian, Liaoning, China
Ochsner Medical Center - North Shore
🇺🇸
Covington, Louisiana, United States
HuaShan Hospital Affiliated To Fudan University
🇨🇳
Shanghai, Shanghai, China
The First Affiliated Hospital of Wenzhou Medical College
🇨🇳
WenZhou, Zhejiang, China
Universitair Ziekenhuis Brussel
🇧🇪
Brussel, Belgium
Jiangsu Province Hospital
🇨🇳
Nanjing, Nanjing, China
Shengli Oilfield Central Hospital
🇨🇳
Dongying, Shandong, China
People's hospital of Rizhao
🇨🇳
Rizhao, Shandong, China
DADO MEDICAL, s.r.o.
🇨🇿
Praha 2, Czechia
Nevada Headache Institute
🇺🇸
Las Vegas, Nevada, United States
Neurologicka ordinace
🇨🇿
Praha 6, Czechia
First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳
Xi'an, Shaanxi, China
Baotou Central Hospital
🇨🇳
Baotou, China
Valeomed Kft.
🇭🇺
Esztergom, Komarom-Esztergom, Hungary
No 1 Affiliate Hospital of Kunming Medical College
🇨🇳
Kunming, Yunnan, China
SE Neurologiai Klinika
🇭🇺
Budapest, Hungary
CCBR-Alborg-DK
🇩🇰
Alborg, Denmark
Glostrup Hospital
🇩🇰
Glostrup, Denmark
Centre Hospitalier Annecy Genevois - Site d'Annecy
🇫🇷
Metz-Tessy, France
DataMed Klinische Studien GmbH
🇩🇪
Köln, Nordrhein-Westfalen, Germany
CHU de Rouen Hopital Charles Nicolle
🇫🇷
Rouen Cedex, France
Chinese PLA General Hospital
🇨🇳
Beijing, China
Mangala Hospitals & Mangala Kidney Foundation
🇮🇳
Mangalore, Karnataka, India
Neurologicka ambulance, Neurologie Brno s.r.o.
🇨🇿
Brno, Czechia
Neurologicka ambulance Prerov
🇨🇿
Prerov, Czechia
Synexus Clinical Research GmbH
🇩🇪
Berlin, Germany
APHM Hôpital de la Timone
🇫🇷
Marseille Cedex 5, France
Istituto Neurologico Carlo Besta
🇮🇹
Milano, Italy
Medical Care and Research, S.A. de C.V.
🇲🇽
Merida, Yucatan, Mexico
Instituto de Investigaciones Aplicadas a la Neurociencia A.C
🇲🇽
Durango, Mexico
Hospital Universitario Marques De Valdecilla
🇪🇸
Santander, Cantabria, Spain
HCG Manavata Cancer Centre
🇮🇳
Nasik, Maharashtra, India
Orszagos Idegtudomanyi Intezet
🇭🇺
Budapest, Hungary
Apollo Hospitals International Ltd.
🇮🇳
Ahmedabad, Gujarat, India
Artemis Hospital
🇮🇳
Gurgaon, Haryana, India
M S Ramaiah Medical College Hospital
🇮🇳
Bangalore, Karnataka, India
Sir Ganga Ram Hospital
🇮🇳
New Delhi, India
Boerhaave Medisch Centrum
🇳🇱
Amsterdam, Netherlands
Isala Klinieken
🇳🇱
Zwolle, Netherlands
Ospedale Bellaria
🇮🇹
Bologna, Italy
CHU St Etienne Hopital Nord
🇫🇷
Saint Etienne Cedex 2, France
Hopital Lariboisière
🇫🇷
Paris, France
Hospital Universitari Vall d'Hebron
🇪🇸
Barcelona, Spain
Inselspital Bern
🇨🇭
Bern, Switzerland
Hull Royal Infirmary
🇬🇧
Hull, East Yorkshire, United Kingdom
Hospital Universitari de Bellvitge
🇪🇸
L'Hospitalet de Llobregat, Barcelona, Spain
Rehaclinic Bad Zurzach
🇨🇭
Bad Zurzach, Switzerland
First Moscow State Medical University n.a. Sechenov
🇷🇺
Moscow, Russian Federation
Clinica Universitaria De Navarra
🇪🇸
Pamplona, Navarra, Spain
Medis Priokskiy
🇷🇺
Nizhny Novgorod, Russian Federation
Hospital Universitario Virgen del Rocio
🇪🇸
Sevilla, Spain
Hospital Universitario La Paz
🇪🇸
Madrid, Spain
Kantonsspital Luzern
🇨🇭
Luzern 16, Luzern, Switzerland
Synexus Merseyside Clinical Research Centre
🇬🇧
Liverpool, Merseyside, United Kingdom
Synexus Hexham General Hospital
🇬🇧
Hexham, Northumberland, United Kingdom
Synexus Wales Clinical Research Centre
🇬🇧
Cardiff, South Glamorgan, United Kingdom
Synexus Thames Valley Clinical Research Centre
🇬🇧
Reading, Berkshire, United Kingdom
Hospital Clinico Universitario de Valladolid
🇪🇸
Valladolid, Spain
H.C.U. Lozano Blesa
🇪🇸
Zaragoza, Spain
Kings College Hospital
🇬🇧
London, Greater London, United Kingdom
Re-Cognition Health Ltd
🇬🇧
Birmingham, West Midlands, United Kingdom
Hospital Clínico Universitario de Valencia
🇪🇸
Valencia, Spain
Hospital Universitario La Fe de Valencia
🇪🇸
Valencia, Spain
Gemeinschaftspraxis für Neurologie und Psychiatrie
🇩🇪
Westerstede, Niedersachsen, Germany
Charité Universitätsmedizin Berlin
🇩🇪
Berlin, Germany
DRK-Kliniken Nordhessen
🇩🇪
Kassel, Hessen, Germany
Neurologische Praxis Eppendorf
🇩🇪
Hamburg, Germany
Dent Neurological Institute
🇺🇸
Amherst, New York, United States
Northwest Clinical Research Center
🇺🇸
Bellevue, Washington, United States
PANAKEIA - Arzneimittelforschung Leipzig GmbH
🇩🇪
Leipzig, Germany
Gobind Ballabh Pant Hospital
🇮🇳
New Delhi, India
Fondazione Istituto Neurologico Nationale C. Mondino
🇮🇹
Pavia, Italy
UCSD Altman Clinical & Translational Research Institute (ACTRI)
🇺🇸
La Jolla, California, United States
StudyMetrix Research, LLC
🇺🇸
Saint Peters, Missouri, United States
George Washington University Medical Center
🇺🇸
Washington, District of Columbia, United States
Universitair Ziekenhuis Gent
🇧🇪
Gent, Belgium
The University of Hong Kong-Shenzhen Hospital
🇨🇳
Shenzhen, Guangdong, China
Pingxiang People's Hospital
🇨🇳
Pingxiang, Jiangxi, China
Hebei General Hospital
🇨🇳
ShiJiazhuang, Hebei, China
First hospital affiliated to Zhengzhou University
🇨🇳
Zhengzhou, Henan, China
Xiangya Hospital, Central South University
🇨🇳
Changsha, Hunan, China
Clintrial, s.r.o.
🇨🇿
Praha 10, Hl. M. Praha, Czechia
Brain-Soultherapy s.r.o
🇨🇿
Kladno, Czechia
Praxis Dr. Philipp Stude
🇩🇪
Bochum, Nordrhein-Westfalen, Germany
Universitätsklinikum Jena
🇩🇪
Jena, Thüringen, Germany
Nizam's Institute of Medical Sciences
🇮🇳
Hyderabad, Andhra Pradesh, India
Kokilaben Dhirubhai Ambani Hospital &Medical Research Inst.
🇮🇳
Mumbai, Maharashtra, India
CRI Centro Regiomontano de Investigacion S.C.
🇲🇽
Monterrey, Nuevo Leon, Mexico
University Headache Clinic
🇷🇺
Moscow, Russian Federation
Saint Petersburg State Medical University n.a. Pavlov I.P.
🇷🇺
Saint Petersburg, Russian Federation
KopfwehZentrum Hirslanden Zürich
🇨🇭
Zollikon, Zurich, Switzerland
Synexus Scotland Clinical Research Centre
🇬🇧
Glasgow, Strathclyde, United Kingdom
Kantonsspital St. Gallen
🇨🇭
St. Gallen, Sankt Gallen, Switzerland
Synexus Manchester Clinical Research Centre
🇬🇧
Manchester, Greater Manchester, United Kingdom
Synexus Midlands Clinical Research Center
🇬🇧
Birmingham, Wstmid, United Kingdom
Hospital Universitario Dr. Jose Eleuterio Gonzalez
🇲🇽
Monterrey, Nuevo Leon, Mexico
Synexus Lancashire Clinical Research Centre
🇬🇧
Chorley, Lancashire, United Kingdom
Algemeen Ziekenhuis St Jan Brugge
🇧🇪
Brugge, Belgium
Queen Elizabeth University Hospital
🇬🇧
Glasgow, Scotland, United Kingdom
AKH
🇦🇹
Wien, Austria
CHC MontLégia
🇧🇪
Liege, Belgium
Eci Estudios Clinicos Int.
🇲🇽
Puebla, Mexico
Christian-Doppler-Klinik
🇦🇹
Salzburg, Austria
Jessa Ziekenhuis
🇧🇪
Hasselt, Limburg, Belgium
Valdor - ISOSL CCV - Clinique des céphalées du Valdor - Neurology
🇧🇪
Liege, Belgium
Istituto Neurologico Neuromed
🇮🇹
Pozzilli, Isernia, Italy
Clinical Research Institute S C
🇲🇽
Tlalnepantla, Edo De Mex, Mexico
Centro de Atención e Investigación Cardiovascular del Potosí S.C.
🇲🇽
San Luis Potosi, Mexico
Canisius-Wilhelmina Ziekenhuis
🇳🇱
Nijmegen, Gelderland, Netherlands
Clinstile, S.A de C.V
🇲🇽
Cuauhtemoc, Federal District, Mexico
Deenanth Mangeshkar Hospital and Research Centre
🇮🇳
Pune, Maharashtra, India